Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Randomized, Blinded, Dose-Determined Study Evaluating the Safety and Tolerability Profile of Intervention With AT-100 (rhSP-D) in Preterm Neonates at High Risk for the Development of Bronchopulmonary Dysplasia (BPD)

Next Previous
Trial Profile

A Phase 1b, Randomized, Blinded, Dose-Determined Study Evaluating the Safety and Tolerability Profile of Intervention With AT-100 (rhSP-D) in Preterm Neonates at High Risk for the Development of Bronchopulmonary Dysplasia (BPD)

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zelpultide alfa (Primary)
  • Indications Bronchopulmonary dysplasia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Airway Therapeutics

    • Most Recent Events

    • 05 Jun 2023 According to an Airway Therapeutics media release, last of 12 patients recruited into the fourth and final cohort of the study has been treated. The fourth cohort began recruitment March 28, 2023, following a Data Safety Monitoring Committee (DSMC) report finding no safety concerns at the conclusion of the trial's dose escalation portion, and included the extremely preterm neonates born as early as weeks 23 and 24.
    • 05 Jun 2023 According to an Airway Therapeutics media release, Interim analysis has been completed and full results are expected by October 2023.
    • 05 Jun 2023 According to an Airway Therapeutics media release, company announced today it successfully completed enrollment in its Phase 1b trial of zelpultide alfa. A total of 37 infants were enrolled at 20 hospitals in the U.S. and Spain.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top